Jilin Tiansanqi Phamarceutical Co. Ltd.

The pharmacokinetic characteristics of hydroxysafflor yellow A for injection after single intravenous infusion of 50 mg, 75 mg and 100 mg, as well as the pharmacokinetic characteristics of 75 mg administered for 7 consecutive days were evaluated in healthy adult subjects.

To evaluate the pharmacokinetic properties of 75 mg of hydroxysafflor yellow A for injection after daily intravenous infusion for 14 consecutive days in healthy adult subjects.

To evaluate the efficacy and safety of hydroxysafflor yellow A for injection in the treatment of stroke, meridian obstruction, and blood stasis syndrome.